CTOs on the Move

Perspective Therapeutics

www.perspectivetherapeutics.com

 
We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medical Specialties Distributors

Medical Specialties Distributors is a Stoughton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolinq

Biolinq develops skin-applied electrochemical sensors that analyze body fluids to provide actionable health information. Get blood level info, without accessing blood.

Chattanooga Canada

Chattanooga Canada Inc. is a Vaudreuil-Dorion, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lab Vision Corporation

Lab Vision Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insulet

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.